SG11201609993YA - Treatment of immune disorders - Google Patents

Treatment of immune disorders

Info

Publication number: SG11201609993YA
Authority: SG; Singapore
Prior art keywords: treatment; immune disorders; immune; disorders
Prior art date: 2014-06-10

Application number

SG11201609993YA

Inventor

Silviu Itescu

Paul Simmons

Original Assignee

Mesoblast Internat Sàrl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-10

Filing date

2015-06-01

Publication date

2016-12-29

2014-06-10 Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en

2015-06-01 Application filed by Mesoblast Internat Sàrl filed Critical Mesoblast Internat Sàrl

2016-12-29 Publication of SG11201609993YA publication Critical patent/SG11201609993YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Biotechnology (AREA)
Virology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)

SG11201609993YA 2014-06-10 2015-06-01 Treatment of immune disorders SG11201609993YA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2014902194A AU2014902194A0 (en)		2014-06-10	Treatment of immune disorders
AU2014902257A AU2014902257A0 (en)		2014-06-13	Treatment of immune disorders 2
PCT/EP2015/062138 WO2015189063A1 (en)	2014-06-10	2015-06-01	Treatment of immune disorders

Publications (1)

Publication Number	Publication Date
SG11201609993YA true SG11201609993YA (en)	2016-12-29

Family

ID=53385603

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201609993YA SG11201609993YA (en)	2014-06-10	2015-06-01	Treatment of immune disorders

Country Status (10)

Country	Link
US (3)	US10624930B2 (en)
EP (2)	EP3154565B1 (en)
JP (4)	JP6800757B2 (en)
KR (3)	KR20170007854A (en)
CN (2)	CN114129598A (en)
AU (2)	AU2015273799B2 (en)
CA (1)	CA2950804C (en)
HK (1)	HK1231386A1 (en)
SG (1)	SG11201609993YA (en)
WO (1)	WO2015189063A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103841983B (en) *	2011-06-03	2018-11-02	麦瑟布莱斯特公司	The method for treating or preventing neurogenic disease
TWI812867B (en)	2011-11-30	2023-08-21	安斯泰來再生醫藥協會	Methods of generating mesenchymal stromal cells using hemangioblasts
CA2950804C (en)	2014-06-10	2023-08-22	Mesoblast International Sarl	Treatment of immune disorders
EP3600354B1 (en) *	2017-03-31	2023-09-20	Wisconsin Alumni Research Foundation	Generation of therapeutic cells using extracellular components of target organs
CN106929474B (en) *	2017-03-31	2021-09-14	北京恒峰铭成生物科技有限公司	M2 macrophage inducer
US20210393700A1 (en) *	2017-11-29	2021-12-23	Figene, Llc	Interaction of fibroblasts and immune cells for activation and uses thereof
CN112007165B (en) *	2020-08-27	2021-10-08	北京大学人民医院	Macrophage polarization regulator and application thereof in promoting thrombopoiesis
WO2024121819A1 (en) *	2022-12-09	2024-06-13	Mesoblast International Sarl	Method of treating inflammation with cellular compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5486359A (en)	1990-11-16	1996-01-23	Osiris Therapeutics, Inc.	Human mesenchymal stem cells
AU2003901668A0 (en)	2003-03-28	2003-05-01	Medvet Science Pty. Ltd.	Non-haemopoietic precursor cells
CN101103101B (en) *	2004-09-24	2012-10-10	成血管细胞系统公司	Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
KR101682046B1 (en)	2005-04-12	2016-12-02	메소블라스트, 아이엔씨.	Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP2367932B1 (en) *	2008-11-19	2019-06-12	Celularity, Inc.	Amnion derived adherent cells
JP5678360B2 (en) *	2009-09-28	2015-03-04	株式会社ジーシー	Method for culturing mesenchymal stem cells
WO2012051210A2 (en) *	2010-10-11	2012-04-19	The Administrators Of The Tulane Educational Fund	Mesenchymal stem cells and related therapies
TWI812867B (en) *	2011-11-30	2023-08-21	安斯泰來再生醫藥協會	Methods of generating mesenchymal stromal cells using hemangioblasts
CN102899293A (en) *	2012-11-01	2013-01-30	上海市肺科医院	Mesenchymal stem cells genetically modified with angiopoietin 1 gene and construction method and application thereof
EP4137560A1 (en) *	2014-04-07	2023-02-22	Mesoblast International Sàrl	Improved stem cell composition
CA2950804C (en)	2014-06-10	2023-08-22	Mesoblast International Sarl	Treatment of immune disorders

2015
- 2015-06-01 CA CA2950804A patent/CA2950804C/en active Active
- 2015-06-01 EP EP15728457.1A patent/EP3154565B1/en active Active
- 2015-06-01 CN CN202111351585.8A patent/CN114129598A/en active Pending
- 2015-06-01 US US15/317,673 patent/US10624930B2/en active Active
- 2015-06-01 EP EP22187393.8A patent/EP4137146A1/en active Pending
- 2015-06-01 AU AU2015273799A patent/AU2015273799B2/en active Active
- 2015-06-01 WO PCT/EP2015/062138 patent/WO2015189063A1/en active Application Filing
- 2015-06-01 SG SG11201609993YA patent/SG11201609993YA/en unknown
- 2015-06-01 CN CN201580030754.4A patent/CN106659743B/en active Active
- 2015-06-01 KR KR1020177000032A patent/KR20170007854A/en not_active IP Right Cessation
- 2015-06-01 KR KR1020237007387A patent/KR102704978B1/en active IP Right Grant
- 2015-06-01 KR KR1020247029823A patent/KR20240135079A/en not_active Application Discontinuation
- 2015-06-01 JP JP2016572424A patent/JP6800757B2/en active Active
2017
- 2017-05-19 HK HK17105054.3A patent/HK1231386A1/en unknown
2020
- 2020-03-24 US US16/828,121 patent/US11406669B2/en active Active
- 2020-09-28 AU AU2020244403A patent/AU2020244403B2/en active Active
- 2020-11-25 JP JP2020195123A patent/JP7009594B2/en active Active
2022
- 2022-01-12 JP JP2022003013A patent/JP7279212B2/en active Active
- 2022-07-22 US US17/870,936 patent/US20230141347A1/en active Pending
2023
- 2023-05-09 JP JP2023077363A patent/JP2023090901A/en active Pending

Also Published As

Publication number	Publication date
JP2022040254A (en)	2022-03-10
EP3154565B1 (en)	2023-05-03
US11406669B2 (en)	2022-08-09
CN106659743B (en)	2022-03-01
CN106659743A (en)	2017-05-10
AU2015273799A1 (en)	2016-12-15
WO2015189063A1 (en)	2015-12-17
US20200281984A1 (en)	2020-09-10
KR20240135079A (en)	2024-09-10
KR102704978B1 (en)	2024-09-09
US20230141347A1 (en)	2023-05-11
CA2950804C (en)	2023-08-22
JP2021028337A (en)	2021-02-25
JP7279212B2 (en)	2023-05-22
EP4137146A1 (en)	2023-02-22
AU2015273799B2 (en)	2020-07-02
JP7009594B2 (en)	2022-02-10
US10624930B2 (en)	2020-04-21
JP2023090901A (en)	2023-06-29
HK1231386A1 (en)	2017-12-22
CN114129598A (en)	2022-03-04
US20170106023A1 (en)	2017-04-20
EP3154565A1 (en)	2017-04-19
AU2020244403A1 (en)	2020-10-29
JP2017526619A (en)	2017-09-14
JP6800757B2 (en)	2020-12-16
CA2950804A1 (en)	2015-12-17
AU2020244403B2 (en)	2024-03-07
KR20170007854A (en)	2017-01-20
KR20230038590A (en)	2023-03-20

Publication	Publication Date	Title
IL285151A (en)	2021-08-31	Methods of treating fgf21-associated disorders
IL252839A0 (en)	2017-08-31	Treatment of pemphigus
GB201701673D0 (en)	2017-03-15	Methods of well treatment
PL3851537T3 (en)	2024-09-16	Treatment of hyperbilirubinemia
IL285003A (en)	2021-08-31	Treatment of joint conditions
SG11201609652RA (en)	2016-12-29	Treatment of polybacterials infections
HK1231386A1 (en)	2017-12-22	Treatment of immune disorders
GB201410116D0 (en)	2014-07-23	Method of treatment
HK1244711A1 (en)	2018-08-17	Treatment of hmgb1-mediated inflammation
IL253028B (en)	2019-12-31	Method of treatment
GB201416832D0 (en)	2014-11-05	Methods of treatment
GB201408387D0 (en)	2014-06-25	Treatment of respiratory disorders
GB201412578D0 (en)	2014-08-27	Treatment of neurological diseases
SG11201702700UA (en)	2017-04-27	Methods for the treatment of peri-implantitis
GB201607388D0 (en)	2016-06-15	Treatment of impulsivity-related disorders
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201411027D0 (en)	2014-08-06	Treatment
GB201512139D0 (en)	2015-08-19	Methods of treatment
GB201412411D0 (en)	2014-08-27	Treatment
AU2014902194A0 (en)	2014-06-26	Treatment of immune disorders
AU2014902257A0 (en)	2014-07-03	Treatment of immune disorders 2
GB201602784D0 (en)	2016-03-30	New treatment of CFTR-related disorders
GB201414023D0 (en)	2014-09-24	Treatment of autoimmune diseases
PT3851537T (en)	2024-03-06	Treatment of hyperbilirubinemia
GB201421980D0 (en)	2015-01-21	Method of treatment